Genomic evidence for recent positive selection at the human MDR1 gene locus.

The MDR1 multidrug transporter regulates the traffic of drugs, peptides and xenobiotics into the body as well as sensitive tissues like the brain, germ cells and the developing fetus. Hence, it may influence an individual's response to drugs as well as his/her susceptibility to complex diseases in which environmental factors, especially xenobiotics, play a role. Polymorphisms within this gene, especially single-nucleotide polymorphism e26/3435(C/T), have been variously associated with differences in MDR1 expression, function, drug response and disease susceptibility. Here, we report the detailed characterization of the haplotype and linkage disequilibrium architecture of the entire 200 kb of the MDR1 gene in five world populations, namely, Chinese, Malays, Indians, Caucasians and African-Americans. We observed varied haplotype diversity across the entire gene in the different populations. The major haplotype mh5, which contains the subhaplotype e12/1236T-e21/2677T-e26/3435T, is highly represented among the four non-African populations, while mh7, which contains the subhaplotype e12/1236C-e21/2677G-e26/3435C, accounts for over a third of African-American chromosomes. These observations are inconsistent with a simple population evolution model, but instead are suggestive of recent historical events that have maintained such long range linkage disequilibrium. Using a modified long-range haplotype test, we found statistically significant evidence of recent positive selection for the e21/2677T and e26/3435T alleles in the Chinese population, and for the e26/3435T allele in the Malay population. Interestingly, we also detected evidence for positive selection of the alternative allele e26/3435C in the African-American population. These data suggest that independent mutational events may have occurred on the mh5 and mh7 haplotypes of the MDR1 gene to confer positive selection in the non-African and African-American populations, respectively.

[1]  M. Fromm,et al.  The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. , 2001, Pharmacogenetics.

[2]  U. Brinkmann,et al.  The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels , 2001, The Pharmacogenomics Journal.

[3]  Werner Siegmund,et al.  The effects of the human MDR1 genotype on the expression of duodenal P‐glycoprotein and disposition of the probe drug talinolol , 2002, Clinical pharmacology and therapeutics.

[4]  Michael F. Hammer,et al.  A recent common ancestry for human Y chromosomes , 1995, Nature.

[5]  M. Stoneking,et al.  Neandertal DNA Sequences and the Origin of Modern Humans , 1997, Cell.

[6]  Jan Stankiewicz,et al.  Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. , 2003, Pharmacogenetics.

[7]  A. Seelig How does P-glycoprotein recognize its substrates? , 1998, International journal of clinical pharmacology and therapeutics.

[8]  F. Sharom,et al.  Interaction of the P-glycoprotein Multidrug Transporter with Peptides and Ionophores (*) , 1995, The Journal of Biological Chemistry.

[9]  Lewontin Rc,et al.  Annotation: the analysis of variance and the analysis of causes. , 1974 .

[10]  Jacques Fellay,et al.  Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study , 2002, The Lancet.

[11]  I. Pastan,et al.  Effect of ABC transporters on HIV‐1 infection: inhibition of virus production by the MDR1 transporter , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.

[13]  Yusuke Nakamura,et al.  Gene-based SNP discovery as part of the Japanese Millennium Genome Project: identification of 190 562 genetic variations in the human genome , 2002, Journal of Human Genetics.

[14]  J. Kigawa,et al.  Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. , 2001, The Journal of pharmacology and experimental therapeutics.

[15]  M. Eichelbaum,et al.  Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. , 2002, Pharmacogenetics.

[16]  M. Gottesman,et al.  HIV-1 protease inhibitors and the MDR1 multidrug transporter. , 1998, The Journal of clinical investigation.

[17]  U. Brinkmann,et al.  Modulation of steady‐state kinetics of digoxin by haplotypes of the P‐glycoprotein MDR1 gene , 2002, Clinical pharmacology and therapeutics.

[18]  S. Higuchi,et al.  Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. , 2001, Pharmacogenetics.

[19]  A. Schinkel,et al.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. , 1996, The Journal of clinical investigation.

[20]  U. Brinkmann,et al.  Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. , 2003, Gastroenterology.

[21]  M. Gottesman,et al.  Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. , 2002, Molecular pharmacology.

[22]  S. Liu-Cordero Patterns of linkage disequilibrium in the human genome , 2002 .

[23]  J. Pritchard,et al.  Linkage disequilibrium in humans: models and data. , 2001, American journal of human genetics.

[24]  A. Chakravarti,et al.  Linkage disequilibrium and haplotype diversity in the genes of the renin-angiotensin system: findings from the family blood pressure program. , 2003, Genome research.

[25]  E. Schuetz,et al.  The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. , 2002, Human immunology.

[26]  L R Cardon,et al.  Extent and distribution of linkage disequilibrium in three genomic regions. , 2001, American journal of human genetics.

[27]  D. Nelson,et al.  Haplotypes at ATM identify coding-sequence variation and indicate a region of extensive linkage disequilibrium. , 2000, American journal of human genetics.

[28]  Christian Meisel,et al.  MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. , 2002, British journal of clinical pharmacology.

[29]  R. Kim,et al.  Identification of functionally variant MDR1 alleles among European Americans and African Americans , 2001, Clinical pharmacology and therapeutics.

[30]  M. Kasuga,et al.  Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. , 2002, Biological & pharmaceutical bulletin.

[31]  J. Stephens,et al.  Haplotype Variation and Linkage Disequilibrium in 313 Human Genes , 2001, Science.

[32]  U. Hofmann,et al.  MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. , 2002, British journal of clinical pharmacology.

[33]  S. Cichon,et al.  Can long-range microsatellite data be used to predict short-range linkage disequilibrium? , 2002, Human molecular genetics.

[34]  L. Excoffier,et al.  Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. , 1995, Molecular biology and evolution.

[35]  Pardis C Sabeti,et al.  Linkage disequilibrium in the human genome , 2001, Nature.

[36]  Yoshinori Morita,et al.  MDR1 Genotype-Related Pharmacokinetics of Digoxin After Single Oral Administration in Healthy Japanese Subjects , 2001, Pharmaceutical Research.

[37]  P. Joyce,et al.  A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression , 2002, The Pharmacogenomics Journal.

[38]  Pardis C Sabeti,et al.  Detecting recent positive selection in the human genome from haplotype structure , 2002, Nature.

[39]  R. Lewontin,et al.  Annotation: the analysis of variance and the analysis of causes. , 2006, American journal of human genetics.

[40]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Marek Kimmel,et al.  Haplotype and linkage disequilibrium architecture for human cancer-associated genes. , 2002, Genome research.

[42]  I. Pastan,et al.  HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. , 1998, Biochemistry.

[43]  Benjamin Yakir,et al.  Linkage disequilibrium patterns of the human genome across populations. , 2003, Human molecular genetics.

[44]  Richard R. Hudson,et al.  Generating samples under a Wright-Fisher neutral model of genetic variation , 2002, Bioinform..

[45]  P. Sonneveld,et al.  MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. , 2001, Blood.

[46]  E. Schuetz,et al.  Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[47]  Kun Tang,et al.  Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. , 2002, Pharmacogenetics.

[48]  Keizo Sugimachi,et al.  Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene , 2002, Transplantation.

[49]  M. Alary,et al.  Allele frequency of three functionally active polymorphisms of the MDR-1 gene in high-risk HIV-negative and HIV-positive Caucasians. , 2002, AIDS.

[50]  R. Kim,et al.  MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. , 2002, Cancer research.

[51]  P. Borst,et al.  What have we learnt thus far from mice with disrupted P-glycoprotein genes? , 1996, European journal of cancer.

[52]  S. Pääbo,et al.  Mitochondrial genome variation and the origin of modern humans , 2000, Nature.

[53]  U. Brinkmann,et al.  Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. , 2002, Journal of the American Society of Nephrology : JASN.

[54]  M. Fromm,et al.  Genetic polymorphisms of the human MDR1 drug transporter. , 2003, Annual review of pharmacology and toxicology.

[55]  P. Deloukas,et al.  Comparison of human genetic and sequence-based physical maps , 2001, Nature.

[56]  A. Puri,et al.  P‐glycoprotein‐overexpressing multidrug‐resistant cells are resistant to infection by enveloped viruses that enter via the plasma membrane 1 , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[57]  D. Goldstein,et al.  Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. , 2003, The New England journal of medicine.

[58]  Y. Cheung,et al.  MDR1, the blood–brain barrier transporter, is associated with Parkinson’s disease in ethnic Chinese , 2004, Journal of Medical Genetics.

[59]  K. Tang,et al.  Simultaneous genotyping of seven single-nucleotide polymorphisms in the MDR1 gene by single-tube multiplex minisequencing. , 2003, Clinical chemistry.

[60]  G R Lankas,et al.  Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. , 1998, Reproductive toxicology.